(Q36619276)

15 August 2017

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc (English)

1 reference

15 August 2017

1 reference

Kuhn W

1

1 reference

15 August 2017

Schmalfeldt B

2

1 reference

15 August 2017

Reuning U

3

1 reference

15 August 2017

Pache L

4

1 reference

15 August 2017

Berger U

5

1 reference

15 August 2017

Ulm K

6

1 reference

15 August 2017

Harbeck N

7

1 reference

15 August 2017

Späthe K

8

1 reference

15 August 2017

Dettmar P

9

1 reference

15 August 2017

Höfler H

10

1 reference

15 August 2017

Jänicke F

11

1 reference

15 August 2017

Schmitt M

12

1 reference

15 August 2017

Graeff H

13

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

79

1 reference

15 August 2017

1746-1751

1 reference

15 August 2017

11-12

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690278

15 August 2017

0 references

cites work

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Regulation of integrin function by the urokinase receptor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Novel methods for the determination of the angiogenic activity of human tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Plasminogen activators, tissue degradation, and cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Radical surgical procedure improves survival time in patients with recurrent ovarian cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Role of cytoreductive surgical treatment in the management of advanced ovarian cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362775

Nonparametric Estimation from Incomplete Observations

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690278

Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690278

The urokinase receptor is a major vitronectin-binding protein on endothelial cells

21 January 2018

1 reference

12 December 2020

The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients

1 reference

12 December 2020

The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors

1 reference

12 December 2020

Urokinase-type plasminogen activator antigen and early relapse in breast cancer

1 reference

12 December 2020

Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study

1 reference

12 December 2020

Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer

1 reference

12 December 2020

Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer

1 reference

12 December 2020

Expression and amplification of the HER-2/ neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines

1 reference

12 December 2020

Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma

1 reference

12 December 2020

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis

1 reference

12 December 2020

[Developments in the therapy of advanced FIGO III ovarian cancer]

1 reference

12 December 2020

Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary

1 reference

12 December 2020

The plasminogen-activation system in ovarian tumors

1 reference

12 December 2020

Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer

1 reference

12 December 2020

Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma

1 reference

12 December 2020

Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis

1 reference

12 December 2020

Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus

1 reference

12 December 2020

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer

1 reference

12 December 2020

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy

1 reference

12 December 2020

The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer

1 reference

12 December 2020

Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival

1 reference

12 December 2020

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2

1 reference

12 December 2020

Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer

1 reference

12 December 2020

Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6690278

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference